![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Avioq’s HIV Assay for Reactive Samples Gains CE Mark
Avioq’s HIV Assay for Reactive Samples Gains CE Mark
![](https://www.fdanews.com/ext/resources/test/Device_Images6/Avioq_Logo.gif?t=1576721636&width=430)
June 25, 2019
Avioq’s VioOne HIV Profile Supplemental Assay has earned the CE Mark and is seeking distribution partners for Europe.
The enzyme-linked immunosorbent assay (ELISA) confirms and distinguishes between individual antibodies directed to various gene products of HIV-1 and HIV-2 in human serum and blood plasma.
The test is specifically used to confirm the presence of HIV-1 or HIV-2 antibodies in specimens that were repeatedly reactive during diagnostic screening procedures.
Upcoming Events
-
21Oct